Article citationsMore>>

E. Esrailian, E. R. Pantangco, N. L Kyulo, K. Q. Hu and B. A. Runyon, “Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome,” Digestive Diseases and Sciences, Vol. 52, No. 3, 2007, pp. 742-748. doi:10.1007/s10620-006-9312-0

has been cited by the following article:

• TITLE: A Case of Type I Hepatorenal Syndrome Treated with Vasopressin

  AUTHORS: Laura Connor, Geoffrey Teehan

  KEYWORDS: Hepatorenal Syndrome; Vasopressin

  JOURNAL NAME: Open Journal of Nephrology, Vol.3 No.3, September 9, 2013

  ABSTRACT: Hepatorenal syndrome (HRS) is a grave complication of end-stage liver disease and is associated with a very high mortality. This case report described a 42-year-old female with advanced alcohol-induced cirrhosis who developed HRS that was initially treated with Midodrine and Octreotide but renal function continued to deteriorate. Vasopressin therapy was added and HRS was successfully reversed. There are few data available on the use of vasopressin for HRS and this case supports its use in treatment of HRS, particularly in countries where the more widely studied Terlipressin is unavailable. This case also demonstrates that a patient failing one medical therapy for HRS may respond to an alternative or adjunctive therapy. Therefore, this should be attempted to increase the patient’s chance of survival.